Enterprise Value
634.1M
Cash
58.32M
Avg Qtr Burn
-43.89M
Short % of Float
20.03%
Insider Ownership
1.44%
Institutional Own.
25.90%
Qtr Updated
09/30/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rucaparib (Rubraca®) Details Ovarian cancer, Cancer | Failed Discontinued | |
Rucaparib (Rubraca®) Details Prostate cancer, Cancer | Failed Discontinued | |
Rucaparib (Rubraca®) Details Cancer, Prostate cancer | Failed Discontinued |